DOX-loaded mesoporous hydroxyapatite modified by hyaluronic acid can achieve efficient targeted therapy for lung cancer

Abstract

It is a novel therapeutic strategy to suppress tumour growth and metastasis by regulating the interaction between bioactivity ions and the biological process of tumour cells. This study synthesised a mesoporous hydroxyapatite (MHAP)-based nanocarrier for targeted delivery of the anti-cancer drug doxorubicin (DOX). To further strengthen the targeting of DOX-loaded nanocarrier to tumour, HA that could specifically identify receptor on the surface of tumours was functionally modified. The drug release properties curve showed that the MHAP-HA@DOX complex showed pH-sensitive and sustained release properties. Also, the MHAP-HA@DOX complex represented high toxicity against lung cancer A549 cells. Besides, it displayed a significant inhibitory effect on tumour growth rate in tumour-bearing mice, while no evident toxicity for mice was observed. This nano-material is hoped to be an effective and novel nano-drug for lung cancer.

Keywords:

• Targeted delivery
• ion interference
• pH response
• CD44 receptor

Authors’ contributions

Yanjie Hu: Conceptualisation, methodology, and software. Enguo Chen: Data curation and writing—original draft preparation. Jisong Zhang: Visualisation and investigation. Liangliang Dong: Supervision, writing—reviewing and editing. Li Xu: Software and validation.

Disclosure statement

The authors declare that they have no conflicts of interest with the contents of this article.

Ethical statement

The study was approved by the ethics committee of Sir Run Run Shaw Hospital, Zhejiang University School of Medicine (Certificate Number: SRRSH20210514). The methods were carried out in accordance with the approved guidelines.

Data availability statement

No additional data are available.

Additional information

Funding

This work was supported by the Basic public welfare research plan of Zhejiang Province (Grant number: LGF19H010011).